Literature DB >> 8080221

Management of common opioid side effects during long-term therapy of cancer pain.

R K Portenoy1.   

Abstract

For most patients with cancer pain, the primary goal of opioid pharmacotherapy is a satisfactory balance between analgesia and side effects. Consequently, the assessment and treatment of opioid side effects is a fundamental aspect of therapy, which may increase the likelihood of a favourable treatment outcome, potentially allow higher and more efficacious opioid doses, and improve quality of life by reducing other uncomfortable symptoms. This review describes the presentation, assessment and management of adverse neuropsychological and gastrointestinal effects due to opioid drugs. These common side effects pose the major challenge for the clinician who undertakes the long-term opioid therapy of patients with cancer pain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080221

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  5 in total

Review 1.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 2.  Substance abuse issues in cancer pain.

Authors:  Laurie A Whitcomb; Kenneth L Kirsh; Steven D Passik
Journal:  Curr Pain Headache Rep       Date:  2002-06

3.  Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children.

Authors:  R D Hain; A Hardcastle; C R Pinkerton; G W Aherne
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 4.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  Cognitive-affective and somatic side effects of morphine and pentazocine: side-effect profiles in healthy adults.

Authors:  Joseph L Riley; Barbara A Hastie; Toni L Glover; Roger B Fillingim; Roland Staud; Claudia M Campbell
Journal:  Pain Med       Date:  2009-08-07       Impact factor: 3.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.